Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

The OncFive: Top Oncology Articles for the Week of 9/14

September 20th 2025

The FDA held a Type A meeting for RP1 in advanced melanoma, the AACR released its Annual Cancer Progress Report, and more.

Retifanlimab Displaces Chemo Alone as the Frontline Standard of Care in SCAC

September 17th 2025

Retifanlimab is the first and only immunotherapy agent to receive an indication for the frontline treatment of patients with advanced SCAC.

KN026 NDA in Pretreated HER2+ Gastric or GEJ Cancer Accepted by NMPA for Review

September 17th 2025

The NDA seeking approval of KN026 plus chemotherapy in HER2-positive gastric or GEJ cancer has been accepted for review in China.

FDA Approval of Belzutifan Provides Needed Option in Pheochromocytoma or Paraganglioma

September 16th 2025

The FDA approval of belzutifan in patients with pheochromocytoma or paraganglioma is a testament to the power of drug discovery in rare tumor subsets.

The OncFive: Top Oncology Articles for the Week of 8/31

September 6th 2025

FDA grants type A meeting to discuss RP1 BLA in melanoma, CBP/p300 bromodomain inhibitor gets fast track status in NSCLC, and more.

Dr Gangaram-Panday on Definitive Chemoradiotherapy in Esophageal Cancer

September 5th 2025

Sanjiv Gangaram-Panday, PhD, discusses findings from a population-based cohort study of definitive chemoradiotherapy in esophageal adenocarcinoma.

Ventana Assay Earns CE IVDR Approval in EU as Companion Diagnostic in HER2-Expressing Breast and Biliary Tract Cancers

September 5th 2025

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Dr Shameem on Selecting NALIRIFOX vs FOLFIRINOX in Advanced Pancreatic Cancer

September 3rd 2025

Raji Shameem, MD, discusses considerations for selecting between available chemotherapy regimens for patients with advanced pancreatic cancer.

Dr Klempner on the Safety Profile of Givastomig Plus Nivolumab and mFOLFOX6 in Gastric, Esophageal, and GEJ Cancer

September 3rd 2025

Samuel J. Klempner, MD, details the safety profile of givastomig/nivolumab and mFOLFOX6 in CLDN18.2-positive gastric, esophageal, and GEJ cancers.

OncLive’s August EMA Regulatory Recap: Key EU Approvals in Oncology

September 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

Development to Discontinue for ZW171 in Gynecologic, Thoracic, and GI Cancer

September 2nd 2025

The development of ZW171 for gynecologic, thoracic, and GI cancers is being discontinued.

4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation

August 26th 2025

Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

BRF14 Data Demonstrate Long-Term Efficacy of Imatinib in Advanced GIST

August 22nd 2025

The BRF14 study, which examined imatinib in patients with gastrointestinal stromal tumors, has the longest follow-up time in this sarcoma.

Dr Wainberg on Treatment Updates in Gastric Cancer and Biliary Tract Cancer

August 21st 2025

Zev A. Wainberg, MD, MSc, highlighted notable research in gastric cancer and cholangiocarcinoma presented during the 2025 ESMO GI Congress.

Health Canada Approves Nivolumab Plus Ipilimumab for Unresectable MSI-H/dMMR CRC and Unresectable HCC

August 20th 2025

Nivolumab plus ipilimumab earned approval from Health Canada for select patients with unresectable colorectal cancer and hepatocellular carcinoma.

Novocure Files Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer

August 20th 2025

The FDA has received a premarket approval application supported by positive results from the PANOVA-3 trial for Tumor Treating Fields (TTFields)—electric fields that exert physical forces to kill cancer cells via a variety of mechanisms—for locally advanced pancreatic cancer.

ATG-022 Earns Breakthrough Therapy Designation in China for Advanced Gastric/GEJ Adenocarcinoma

August 19th 2025

The NMPA has granted breakthrough therapy designation to ATG-022 for previously treated gastric and gastroesophageal junction adenocarcinoma.

How Chemoimmunotherapy, PRRT, and First-Line Immunotherapy Are Reshaping GI Cancer Management

August 12th 2025

Tanios S. Bekaii-Saab, MD, discusses evolving frontline and evolving treatment strategies in esophageal cancer, HCC, and NETs.

Dr O’Reilly on the Potential of TTFields in Unresectable, Locally Advanced Pancreatic Cancer

August 11th 2025

Eileen M. O’Reilly, MD, discusses the potential of tumor treating fields for the treatment of patients with locally advanced pancreatic cancer.